Form 8-K - Current report:
SEC Accession No. 0001140361-25-020409
Filing Date
2025-05-27
Accepted
2025-05-27 07:40:06
Documents
14
Period of Report
2025-05-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20049685_8k.htm   iXBRL 8-K 31157
2 EXHIBIT 99.1 ef20049685_ex99-1.htm EX-99.1 27015
6 image00001.jpg GRAPHIC 11189
  Complete submission text file 0001140361-25-020409.txt   209884

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20250527.xsd EX-101.SCH 3994
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20250527_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20250527_pre.xml EX-101.PRE 16052
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20049685_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 25984210
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)